Annual EBITDA
-$51.13 M
-$17.73 M-53.06%
December 31, 2023
Summary
- As of February 8, 2025, ATNM annual EBITDA is -$51.13 million, with the most recent change of -$17.73 million (-53.06%) on December 31, 2023.
- During the last 3 years, ATNM annual EBITDA has fallen by -$29.18 million (-132.98%).
- ATNM annual EBITDA is now -616124.10% below its all-time high of $8300.00, reached on December 31, 2010.
Performance
ATNM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$12.40 M
-$170.00 K-1.39%
September 30, 2024
Summary
- As of February 8, 2025, ATNM quarterly EBITDA is -$12.40 million, with the most recent change of -$170.00 thousand (-1.39%) on September 30, 2024.
- Over the past year, ATNM quarterly EBITDA has dropped by -$2.25 million (-22.23%).
- ATNM quarterly EBITDA is now -451.93% below its all-time high of $3.52 million, reached on June 30, 2014.
Performance
ATNM Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$44.15 M
+$1.75 M+3.82%
September 30, 2024
Summary
- As of February 8, 2025, ATNM TTM EBITDA is -$44.15 million, with the most recent change of +$1.75 million (+3.82%) on September 30, 2024.
- Over the past year, ATNM TTM EBITDA has increased by +$6.98 million (+13.65%).
- ATNM TTM EBITDA is now -101835.02% below its all-time high of $43.40 thousand, reached on September 30, 2011.
Performance
ATNM TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ATNM EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -53.1% | -22.2% | +13.7% |
| 3 y3 years | -133.0% | -95.7% | -93.3% |
| 5 y5 years | -115.0% | -89.4% | -103.9% |
ATNM EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -109.2% | at low | -146.7% | +19.7% | -82.3% | +15.3% |
| 5 y | 5-year | -136.1% | at low | -173.7% | +19.7% | -119.0% | +15.3% |
| alltime | all time | <-9999.0% | at low | -451.9% | +25.8% | <-9999.0% | +15.3% |
Actinium Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$12.40 M(+1.4%) | -$44.15 M(-3.8%) |
| Jun 2024 | - | -$12.23 M(+30.4%) | -$45.91 M(-6.5%) |
| Mar 2024 | - | -$9.38 M(-7.5%) | -$49.11 M(-4.0%) |
| Dec 2023 | -$51.13 M(+53.1%) | -$10.14 M(-28.3%) | -$51.13 M(-1.9%) |
| Sep 2023 | - | -$14.15 M(-8.3%) | -$52.12 M(+9.6%) |
| Jun 2023 | - | -$15.43 M(+35.4%) | -$47.54 M(+19.5%) |
| Mar 2023 | - | -$11.40 M(+2.4%) | -$39.78 M(+19.1%) |
| Dec 2022 | -$33.41 M(+36.7%) | -$11.13 M(+16.2%) | -$33.41 M(+10.7%) |
| Sep 2022 | - | -$9.58 M(+24.9%) | -$30.19 M(+12.0%) |
| Jun 2022 | - | -$7.67 M(+52.6%) | -$26.94 M(+11.2%) |
| Mar 2022 | - | -$5.03 M(-36.5%) | -$24.22 M(-0.9%) |
| Dec 2021 | -$24.44 M(+11.4%) | -$7.91 M(+24.9%) | -$24.44 M(+7.0%) |
| Sep 2021 | - | -$6.34 M(+28.1%) | -$22.84 M(+3.8%) |
| Jun 2021 | - | -$4.95 M(-5.7%) | -$22.01 M(+1.8%) |
| Mar 2021 | - | -$5.25 M(-16.9%) | -$21.62 M(-1.5%) |
| Dec 2020 | -$21.95 M(+1.4%) | -$6.32 M(+14.8%) | -$21.95 M(+8.9%) |
| Sep 2020 | - | -$5.50 M(+20.8%) | -$20.16 M(-4.9%) |
| Jun 2020 | - | -$4.55 M(-18.3%) | -$21.20 M(-2.0%) |
| Mar 2020 | - | -$5.58 M(+23.1%) | -$21.63 M(-0.1%) |
| Dec 2019 | -$21.65 M(-8.9%) | -$4.53 M(-30.8%) | -$21.65 M(-7.8%) |
| Sep 2019 | - | -$6.54 M(+31.4%) | -$23.47 M(+1.6%) |
| Jun 2019 | - | -$4.98 M(-11.0%) | -$23.11 M(+0.4%) |
| Mar 2019 | - | -$5.59 M(-11.9%) | -$23.03 M(-3.1%) |
| Dec 2018 | -$23.78 M(-11.5%) | -$6.35 M(+2.7%) | -$23.78 M(+5.1%) |
| Sep 2018 | - | -$6.18 M(+26.2%) | -$22.62 M(-2.2%) |
| Jun 2018 | - | -$4.90 M(-22.7%) | -$23.12 M(-9.0%) |
| Mar 2018 | - | -$6.34 M(+22.0%) | -$25.41 M(-5.4%) |
| Dec 2017 | -$26.85 M(+10.8%) | -$5.20 M(-22.2%) | -$26.85 M(-5.2%) |
| Sep 2017 | - | -$6.68 M(-7.0%) | -$28.33 M(+0.4%) |
| Jun 2017 | - | -$7.19 M(-7.7%) | -$28.23 M(+2.1%) |
| Mar 2017 | - | -$7.78 M(+16.6%) | -$27.64 M(+14.0%) |
| Dec 2016 | -$24.24 M(+15.6%) | -$6.68 M(+1.5%) | -$24.24 M(+0.6%) |
| Sep 2016 | - | -$6.58 M(-0.4%) | -$24.09 M(+12.4%) |
| Jun 2016 | - | -$6.60 M(+50.7%) | -$21.44 M(-3.8%) |
| Mar 2016 | - | -$4.38 M(-32.9%) | -$22.29 M(+6.3%) |
| Dec 2015 | -$20.96 M | -$6.53 M(+66.2%) | -$20.96 M(+5.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2015 | - | -$3.93 M(-47.2%) | -$19.84 M(-9.7%) |
| Jun 2015 | - | -$7.45 M(+143.4%) | -$21.98 M(+99.6%) |
| Mar 2015 | - | -$3.06 M(-43.5%) | -$11.01 M(-55.3%) |
| Dec 2014 | -$24.65 M(+128.9%) | -$5.41 M(-10.7%) | -$24.65 M(-1.9%) |
| Sep 2014 | - | -$6.06 M(-272.1%) | -$25.12 M(+22.7%) |
| Jun 2014 | - | $3.52 M(-121.1%) | -$20.47 M(-23.5%) |
| Mar 2014 | - | -$16.70 M(+184.1%) | -$26.78 M(+148.7%) |
| Dec 2013 | -$10.77 M(+48.3%) | -$5.88 M(+314.1%) | -$10.77 M(+41.3%) |
| Sep 2013 | - | -$1.42 M(-49.0%) | -$7.62 M(-14.3%) |
| Jun 2013 | - | -$2.78 M(+304.3%) | -$8.90 M(+21.0%) |
| Mar 2013 | - | -$688.50 K(-74.8%) | -$7.35 M(+1.3%) |
| Dec 2012 | -$7.26 M(+122.1%) | -$2.73 M(+1.3%) | -$7.26 M(-7.1%) |
| Sep 2012 | - | -$2.69 M(+116.9%) | -$7.82 M(+52.5%) |
| Jun 2012 | - | -$1.24 M(+108.4%) | -$5.13 M(+32.7%) |
| Mar 2012 | - | -$595.90 K(-81.9%) | -$3.86 M(+18.1%) |
| Dec 2011 | -$3.27 M(<-9900.0%) | -$3.29 M(>+9900.0%) | -$3.27 M(-7633.9%) |
| Sep 2011 | - | -$2400.00(-111.1%) | $43.40 K(+15.1%) |
| Jun 2011 | - | $21.60 K(-900.0%) | $37.70 K(+211.6%) |
| Mar 2011 | - | -$2700.00(-110.0%) | $12.10 K(+45.8%) |
| Dec 2010 | $8300.00(-152.2%) | $26.90 K(-432.1%) | $8300.00(-131.4%) |
| Sep 2010 | - | -$8100.00(+102.5%) | -$26.40 K(+28.8%) |
| Jun 2010 | - | -$4000.00(-38.5%) | -$20.50 K(+10.2%) |
| Mar 2010 | - | -$6500.00(-16.7%) | -$18.60 K(+16.3%) |
| Dec 2009 | -$15.90 K(-39.5%) | -$7800.00(+254.5%) | -$16.00 K(+11.1%) |
| Sep 2009 | - | -$2200.00(+4.8%) | -$14.40 K(+0.7%) |
| Jun 2009 | - | -$2100.00(-46.2%) | -$14.30 K(-30.2%) |
| Mar 2009 | - | -$3900.00(-37.1%) | -$20.50 K(-22.1%) |
| Dec 2008 | -$26.30 K(+22.3%) | -$6200.00(+195.2%) | -$26.30 K(-22.9%) |
| Sep 2008 | - | -$2100.00(-74.7%) | -$34.10 K(-7.1%) |
| Jun 2008 | - | -$8300.00(-14.4%) | -$36.70 K(+17.6%) |
| Mar 2008 | - | -$9700.00(-30.7%) | -$31.20 K(+45.1%) |
| Dec 2007 | -$21.50 K(+22.9%) | -$14.00 K(+197.9%) | -$21.50 K(+43.3%) |
| Sep 2007 | - | -$4700.00(+67.9%) | -$15.00 K(-26.1%) |
| Jun 2007 | - | -$2800.00(<-9900.0%) | -$20.30 K(+16.0%) |
| Mar 2007 | - | $0.00(-100.0%) | -$17.50 K(0.0%) |
| Dec 2006 | -$17.50 K | -$7500.00(-25.0%) | -$17.50 K(+75.0%) |
| Sep 2006 | - | -$10.00 K | -$10.00 K |
FAQ
- What is Actinium Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Actinium Pharmaceuticals?
- What is Actinium Pharmaceuticals annual EBITDA year-on-year change?
- What is Actinium Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Actinium Pharmaceuticals?
- What is Actinium Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Actinium Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Actinium Pharmaceuticals?
- What is Actinium Pharmaceuticals TTM EBITDA year-on-year change?
What is Actinium Pharmaceuticals annual EBITDA?
The current annual EBITDA of ATNM is -$51.13 M
What is the all time high annual EBITDA for Actinium Pharmaceuticals?
Actinium Pharmaceuticals all-time high annual EBITDA is $8300.00
What is Actinium Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, ATNM annual EBITDA has changed by -$17.73 M (-53.06%)
What is Actinium Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of ATNM is -$12.40 M
What is the all time high quarterly EBITDA for Actinium Pharmaceuticals?
Actinium Pharmaceuticals all-time high quarterly EBITDA is $3.52 M
What is Actinium Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, ATNM quarterly EBITDA has changed by -$2.25 M (-22.23%)
What is Actinium Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of ATNM is -$44.15 M
What is the all time high TTM EBITDA for Actinium Pharmaceuticals?
Actinium Pharmaceuticals all-time high TTM EBITDA is $43.40 K
What is Actinium Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, ATNM TTM EBITDA has changed by +$6.98 M (+13.65%)